Table 1.
Patient characteristics: MM patients.
| Poor mobilizers (n = 8) | Good mobilizers (n = 10) | |
|---|---|---|
| Age, median (range), years | 61 (48–67) | 65.5 (30–73) |
|
| ||
| Sex | ||
| Male Female |
8 0 |
5 5 |
|
| ||
| Disease stage | ||
| II III |
2 6 |
4 6 |
|
| ||
| Disease status | ||
| CR/VGPR PR DP |
2 6 0* |
3 7 0 |
|
| ||
| B2M Chromosome 13q/13 del |
2.74 (1.68–5.84) 2 |
3.09 (1.3–5.18) 4 |
|
| ||
| Median no. of prior treatment regimens (range) | 1 (1–3) | 1 (1–3) |
|
| ||
| Prior lenalidomide (≥4 cycles) | 2 | 0 |
|
| ||
| Prior RT | 2 | 6 |
|
| ||
| Median time from diagnosis (range), days | 206 (129–462) | 204 (109–377) |
|
| ||
| Patients who had two transplants: | ||
| As salvage As tandem |
1 — |
1 1 |
|
| ||
| Posttransplant maintenance** | 5 | 6 |
*One patient was in PR at first mobilization; however, he developed disease progression by the time he went through the plerixafor mobilization. The patient did not go through ASCT, and he was excluded from survival analysis.
**At 3 months of evaluation posttransplant, patients were offered maintenance therapy with thalidomide.
Note. The results show number of patients in each category unless indicated otherwise.